Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cubist Pharmaceuticals LLC
ClinicalTrials.gov Identifier:
NCT00626275
First received: February 22, 2008
Last updated: June 4, 2015
Last verified: June 2015

February 22, 2008
June 4, 2015
October 2007
September 2008   (final data collection date for primary outcome measure)
  • Part A: Average Difference Between Baseline and Post Dose Evoked (by Treadmill Walking) Lower-Extremity Pain Intensity Scores (AELEPID) Over the 6 Hours After Dosing [ Time Frame: Baseline through 6 hours post dose ] [ Designated as safety issue: No ]

    Approximately 1 hour before baseline and again approximately 45 minutes before the 2-, 4-, and 6-hour time points, participants rested for 45 minutes, then they started the treadmill walk at 15 minutes before baseline and at the 2-, 4-, and 6-hour time points. After the treadmill walk, participants were asked to rate their lower extremity pain on an 11 point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. The average difference between baseline and 6 hours post dose evoked lower-extremity pain intensity scores (AELEPID-6) is presented for each treatment group. Difference = predose (baseline) NPRS score - NPRS score 6 hours post dose.

    Least square (LS) means and standard errors (SE) were calculated from an analysis-of-covariance (ANCOVA) model with fixed effects for sequence, treatment, period, predose evoked lower extremity pain intensity as a covariate, and a random effect for participant nested within sequence.

  • Part B: The Mean of Daily Average "Now" Lower Extremity Pain Intensity (LEPI) Score During the 2-Week Period [ Time Frame: Baseline through 2 Weeks ] [ Designated as safety issue: No ]

    Participants assessed their "Now" LEPI 3 times each day (morning, midday, and evening at approximately 10 AM, 2 PM, and 8 PM) and before taking any rescue medication. At each time point, participants were asked to rate their lower extremity pain on an 11-point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. If a scheduled pain assessment was taken within 4 hours of rescue medication, the observed pain score was replaced by the pain score obtained right before the rescue medication was taken.

    LS means and SE were calculated from an analysis-of-covariance model with effect for treatment and baseline "Now" LEPI (before dosing for Treatment Period 1 of Part A) as a covariate. Participants with no postbaseline assessments were excluded from the baseline summary.

Part A (single-dose crossover part): Average difference between baseline and postdose lower extremity pain intensity (LEPI) over 6 hours after repeated treadmill walking. Part B: mean daily LEPI score over 2 weeks. [ Time Frame: 6 hours post dosing and 3xdaily IVRS calls during 2 wks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00626275 on ClinicalTrials.gov Archive Site
  • Part A: Pain Intensity Score (NPRS Score) for Overall Pain, for Lower Extremity Pain, and for Evoked (by Treadmill Walking) Lower Extremity Pain [ Time Frame: Baseline up to 12 hours post dose ] [ Designated as safety issue: No ]
    Overall Pain Intensity (OPI), "Now" Lower Extremity Pain Intensity (LEPI), and Evoked Lower Extremity Pain Intensity (ELEPI) were assessed using the 11-point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. OPI was assessed at 15 minutes before dosing for baseline and at 6 and 12 hours (hr) after dosing. At 15 minutes before dosing, during Period 1 only, participants were also asked to assess their average LEPI over the last 24 hours as a baseline measurement. "Now" LEPI was assessed at 15 minutes before dosing for baseline and at the 1-, 2-, 3-, 4-, 5-, 6-, and 12-hour time points. Approximately 1 hour before dosing and approximately 45 minutes before the 2-, 4-, and 6-hour time points, the participant rested for 45 minutes, then (after the "Now" LEPI assessment) he or she started a treadmill walk at 15 minutes before dosing for baseline and at the 2-, 4-, and 6-hour time points, and then assessed ELEPI.
  • Part B: Mean Daily LEPI Scores for Weeks 1 and 2 [ Time Frame: Baseline through Week 1 and Week 1 through Week 2 ] [ Designated as safety issue: No ]
    Participants assessed their "Now" LEPI 3 times each day (morning, midday, and evening at approximately 10 AM, 2 PM, and 8 PM) and before taking any rescue medication. At each time point, participants were asked to rate their lower extremity pain on an 11 point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. If a scheduled pain assessment was taken within 4 hours of rescue medication, the observed pain score was replaced by the pain score obtained right before the rescue medication was taken.
  • Part A: Pain Intensity Difference Between Baseline and the Value at Each Scheduled Time Point for Overall Pain [ Time Frame: Baseline, 6 and 12 hours post dose ] [ Designated as safety issue: No ]
    Overall Pain Intensity (OPI) was assessed by the participant using the 11-point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. OPI was assessed at 15 minutes before dosing for baseline and at 6 and 12 hours after dosing. Difference = predose (baseline) OPI score - OPI score 6 and 12 hours post dose.
  • Part A: Average Difference Between Baseline and Postdose Evoked Lower Extremity Pain Over the 4 Hours After Dosing [ Time Frame: Baseline, 4 hours post dose ] [ Designated as safety issue: No ]
    Evoked Lower Extremity Pain Intensity (ELEPI) was assessed using the 11-point Numeric Pain Rating Scale (NPRS), with 0 indicating No Pain and 10 indicating Worst Possible Pain. Approximately 1 hour before dosing and approximately 45 minutes before the 2-, 4-, and 6-hour time points, the participant rested for 45 minutes, then he or she started a treadmill walk at 15 minutes before dosing for baseline and at the 2-, 4-, and 6-hour time points, and then assessed ELEPI. Difference = predose (baseline) ELEPI score - ELEPI score 4 hours post dose.
  • Part A: Mean Peak Difference in ELEPI According to the NPRS Scale [ Time Frame: Baseline, Up to 6 hours post dose ] [ Designated as safety issue: No ]
    Evoked Lower Extremity Pain Intensity (ELEPI) was assessed using the 11-point NPRS. Participants were asked to rate their lower extremity pain on an 11 point NPRS, with 0 indicating No Pain and 10 indicating Worst Possible Pain. If a scheduled pain assessment was taken within 4 hours of rescue medication, the observed pain score was replaced by the pain score obtained right before the rescue medication was taken. Approximately 1 hour before dosing and approximately 45 minutes before the 2-, 4-, and 6-hour time points, the participant rested for 45 minutes, then he or she started a treadmill walk at 15 minutes before dosing for baseline and at the 2-, 4-, and 6-hour time points, and then assessed ELEPI. Peak ELEPID was defined as the maximum of ELEPIDs recorded at 2, 4, and 6 hours post dose. Difference = predose (baseline) NPRS score - peak NPRS score up to 6 hours post dose.
  • Part A: Percentage of Participants in Each Treatment Group Achieving a 25%, 50%, or 75% Reduction From Baseline in Evoked Lower Extremity Pain Intensity Scores [ Time Frame: Up to 2, 4, and 6 hours post dosing ] [ Designated as safety issue: No ]
    Percentage was measured by identifying the number of participants who achieved the desired percentage Reduction From Baseline in ELEPI Score at either 2, 4, and 6 hours post dose and was divided the by the number of total participants in the given group and then multiplied by 100 to equate to a percentage.
  • Part B: Participants' Global Evaluation of Study Medication [ Time Frame: Up to Week 1 and Week 2 ] [ Designated as safety issue: No ]
    For Part B, each participant's global evaluation (overall impression) of study medication was obtained at each weekly visit. Scores were recorded on the Case Report Form (CRF) on a 5 point scale ranging from "excellent" to "poor". Participant counts per score were reported at Week 1 (Day 7) and Week 2 (Day 14).
  • Part B: Mean Daily Average LEPI Scores Over the Last 24 Hours at Week 1 and Week 2 [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
    Each day during Part B, participants rated their Lower Extremity Pain Intensity over the last 24 hours on an 11-point NPRS, with 0 indicating No Pain and 10 indicating Worst Possible Pain
  • Part B: Mean Daily Average Overall Pain Intensity Scores Over Week 1, Over Week 2, and Over a 2-Week Period [ Time Frame: Baseline through Week 1, Week 1 through Week 2, and Baseline through Week 2 ] [ Designated as safety issue: No ]
    During Part B, participants returned to the clinic for 2 additional visits at approximately weekly intervals for assessments of Overall Pain Index (OPI). Participants rated their OPI on an 11-point Numeric Pain Rating Scale (NPRS) with 0 indicating No Pain and 10 indicating Worst possible pain
  • Part B: Percentage of Participants Using Rescue Medication [ Time Frame: Baseline through Week 2 ] [ Designated as safety issue: No ]
    The percentage of participants who took at least 1 dose of rescue medication during 2-week treatment period of Part B is presented.
  • Part A: Participant's Global Evaluation of Study Medication [ Time Frame: 6 hours post dose during Treatment Periods 1, 2, and 3 of Part A ] [ Designated as safety issue: No ]
    For each treatment period during Part A, each participant's global evaluation (overall impression) of study medication was obtained 6 hours after dosing. Scores were recorded on the Case Report Form (CRF) on a 5 point scale ranging from "excellent" to "poor". Participant counts per score were reported once in Part A.
  • Part A (single-dose crossover): pain intensity score for overall pain, for lower extremity pain, & for evoked (by treadmill walking) lower extremity pain at each scheduled time point. [ Time Frame: 2, 4, or 6 hours ] [ Designated as safety issue: No ]
  • Part B (multiple-dose comparison with placebo): average daily LEPI scores for Weeks 1 & 2; average daily overall pain intensity scores at Week 1 and Week 2 visits and over the 2 week period; proportion of subjects using rescue [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
  • Part A: Pain intensity difference between baseline and the value at each scheduled time point for overall pain, for lower extremity pain, and for evoked lower extremity pain; [ Time Frame: 2, 4, or 6 hours ] [ Designated as safety issue: No ]
  • Part A: the average difference between baseline and postdose evoked lower extremity pain over the 4 hours after dosing [ Time Frame: 4 hours post dosing ] [ Designated as safety issue: No ]
  • Part A: peak evoked lower extremity pain; average difference between baseline and postdose lower extremity pain intensity at rest over the 6 hours after dosing; [ Time Frame: 6 hours post dosing ] [ Designated as safety issue: No ]
  • Part A: percentage of subjects in each treatment group achieving a 25%, 50%, or 75% reduction in evoked lower extremity pain intensity scores at 2, 4, or 6 hours; [ Time Frame: 2, 4, or 6 hours post dosing ] [ Designated as safety issue: No ]
  • Part A: Proportion of subjects able to walk on a treadmill for their target treadmill walking time; subject's global evaluation of study medication [ Time Frame: Week 1 and Week 2 study visits ] [ Designated as safety issue: No ]
  • Part B (multiple-dose comparison with placebo): average daily lower extremity pain intensity scores for Weeks 1 and 2 [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
  • Part B: Average daily overall pain intensity scores at Week 1 and Week 2 visits and over the 2 week period [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
  • Part B: Proportion of subjects using rescue medication; mean dose of rescue medication for Weeks 1 and 2 and over the 2 week period [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
  • Part B: Subject's global evaluation of study medication at Week 1 and Week 2 visits [ Time Frame: Week 1 and Week 2 ] [ Designated as safety issue: No ]
  • Reports of adverse events, and changes in the results of: clinical laboratory tests, vital signs and ECGs [ Time Frame: Trial duration ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis
A Phase 2a Randomized, Placebo- and Active-Controlled, Single-Dose, 3-Period, Crossover Study Followed by a Randomized, Placebo-Controlled, 14-Day, Parallel-Group Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving pain associated with rheumatoid arthritis (RA) compared with placebo and naproxen (similar to Aleve®). A second objective is to see whether the effect of ADL5859 differs after a single dose compared with multiple doses.
This Phase 2a study was conducted in 2 parts. Part A was a randomized, single-dose, double-blind, placebo- and active-controlled, 3-way crossover phase during which participants were administered study medication in the clinical facility. Part B was a 14-day, randomized, double-blind, placebo-controlled, parallel-group, multiple-dose phase in which participants self-administered study medication at home.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: ADL5859
    Other Name: ADL-5859
  • Drug: Naproxen
    Other Name: Naprosyn
  • Drug: Placebo
    Other Name: Lactose Monohydrate National Formulary (NF)
  • Drug: Placebo
    Other Name: Lactose Monohydrate NF
  • Experimental: ADL5859 -- 200 mg (Part A)
    ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
    Intervention: Drug: ADL5859
  • Active Comparator: Naproxen -- 500 mg (Part A)
    Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
    Intervention: Drug: Naproxen
  • Placebo Comparator: Placebo (Part A)
    Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
    Intervention: Drug: Placebo
  • Experimental: ADL5859 - 100 mg (Part B)
    ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
    Intervention: Drug: ADL5859
  • Placebo Comparator: Placebo (Part B)
    Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
46
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female participants between 18 and 75 years of age, inclusive
  • Have a documented history of rheumatoid arthritis (diagnosed according to American College of Rheumatology criteria)
  • Have painful rheumatoid arthritis with pain predominantly in the lower extremities (that is, hip, knees, ankles, and/or feet)
  • Have an evoked lower extremity pain intensity (ELEPI) score of 5 or higher on a numeric pain rating scale (NPRS) completed on Day 1 of Part A before dosing (after resting for 45 minutes and then walking for at least 10 minutes on a treadmill) and then have a minimum ELEPI score of 4 on other visits during Part A
  • If receiving disease modifying antirheumatic drugs, have a stable dose regimen for at least 30 days before study entry (90 days before study entry for biologic therapy)
  • If biologic therapy has been recently discontinued, Enbrel™ or Orencia™ must have been discontinued at least 30 days before study entry, and Humira™, Remicade™, and Rituxan™ must have been discontinued at least 60 days before study entry
  • For male participants, be surgically sterile or agree to use an appropriate method of contraception
  • For female participants of child bearing potential, be surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the US Food and Drug Administration (FDA) through the completion of the study and have negative findings on a urine pregnancy test before administration of study medication (women who are postmenopausal [no menses for at least 2 years] are also eligible to participate)
  • Have a body weight of at least 45 kilograms (kg)
  • Be able to understand and comply with the protocol requirements (such as repeated treadmill walking and diary completion via the interactive voice response system), instructions, and protocol-specified restrictions.

Exclusion Criteria:

  • Have an overall pain intensity (OPI) score equal to 10 at screening or before the first dose of study medication in Part A
  • Have a pain intensity score for the upper body (that is, back, neck, fingers, wrists, elbows, and/or shoulders) above 7 on a numeric pain rating scale (NPRS) before study medication administration
  • Have a history of headache requiring prescription treatment within 6 months of study entry
  • Have significant renal disease (as indicated by blood urea nitrogen or serum creatinine ≥ 2 times the upper limit of normal) or have significant hepatic disease (as indicated by liver function test results ≥ 2 times the upper limit of normal)
  • Have evidence of symptomatic orthostatic hypotension
  • Have a history of a seizure disorder, including febrile seizures
  • Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that would affect study participation
  • Are taking cytochrome P450 (CYP) 3A4/5 or P glycoprotein (P gp) transporter inhibitors
  • Have taken oral steroids within 30 days of study entry or intra articular steroids within 60 days of study entry (inhaled or topical steroids or stable oral dose ≤ 10 mg is permitted)
  • Have a history or presence of allergy or intolerance to nonsteroidal anti-inflammatory drugs or acetaminophen, or have a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
  • Have a history of alcoholism or drug addiction or abuse within 5 years before the scheduled administration of study medication
  • Have participated in a trial of any investigational medication within 30 days before study drug administration
Both
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00626275
33CL232
No
Not Provided
Not Provided
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC
Not Provided
Study Director: Bruce Berger, MD Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC
June 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP